Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00331526 · ClinicalTrials.gov registry record · Phase 2
Cellular Adoptive Immunotherapy in Treating Patients With Glioblastoma Multiforme
A Phase 2 study, sponsored by Hoag Memorial Hospital Presbyterian.
- Completed
- Registry status
- Phase 2
- Development phase
- 83
- Enrollment target
NCT00331526 is a Phase 2 study that has completed, run by Hoag Memorial Hospital Presbyterian. The registered enrollment target is 83 participants.
The verdict
NCT00331526, a Phase 2 study, has completed, sponsored by Hoag Memorial Hospital Presbyterian.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 83 participants
- Enrollment target
Study Summary
RATIONALE: Biological therapies, such as cellular adoptive immunotherapy, may stimulate the immune system in different ways and stop tumor cells from growing. Aldesleukin may stimulate the white blood cells, including lymphokine-activated killer cells, to kill tumor cells. Giving cellular adoptive immunotherapy during or after surgery may kill more tumor cells. PURPOSE: This phase II trial is studying how well cellular adoptive immunotherapy works in treating patients with glioblastoma multiforme.
Interventions
- PROCEDURE conventional surgery
- BIOLOGICAL therapeutic autologous lymphocytes
- BIOLOGICAL aldesleukin
- PROCEDURE adjuvant therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 83 participants |
| Start Date | 1999-02 |
| Est. Completion | 2012-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00331526
The ClinicalTrials.gov registry entry for NCT00331526 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 83 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoag Memorial Hospital Presbyterian, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which conventional surgery is the first listed.
NCT00331526 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00331526 about?
NCT00331526 is a clinical study titled "Cellular Adoptive Immunotherapy in Treating Patients With Glioblastoma Multiforme". RATIONALE: Biological therapies, such as cellular adoptive immunotherapy, may stimulate the immune system in different ways and stop tumor cells from growing. Aldesleukin may stimulate the white blood cells, including lymphokine-activated killer cells, to kill tumor cells. Giving cellular adoptive i...
What is the current status of trial NCT00331526?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 83 participants. The study started on 1999-02. Estimated completion is 2012-04.
What interventions are being tested in trial NCT00331526?
The interventions under investigation include: conventional surgery (PROCEDURE), therapeutic autologous lymphocytes (BIOLOGICAL), aldesleukin (BIOLOGICAL), adjuvant therapy (PROCEDURE).
Who is sponsoring clinical trial NCT00331526?
This trial is sponsored by Hoag Memorial Hospital Presbyterian, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.